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ABSTRACT | The burden of corneal blindness and visual 
deficiency can be felt worldwide. Its association with several 
endemic diseases such as childhood blindness, trauma, 
infectious keratitis (including variants caused by herpes, 
hanseniasis, and fungi), vitamin A deficiency, diabetes mellitus, 
and other dry eye syndromes reflects its poorly understood 
underlying mechanisms and suggests that the actual frequency 
of the disease is underestimated. The low effectiveness of 
preventive and therapeutic strategies against corneal scarring 
or deformity predicts a high frequency of patients with corneal 
blindness in the future. Corneal blindness is associated with 
environmental factors and socioeconomic limitations that 
restrain health assistance and maintain a modest efficiency 
of the current therapeutic strategies for resolving corneal diseases 
in large-scale programs. We present here a critical review of 
the concepts associated with corneal blindness that need to 
be considered when planning strategies to prevent and treat 
corneal blindness worldwide (to be able to leave Plato’s cave, 
where corneal blindness is encaged.
Keywords: Blindness/epidemiology; Blindness/prevent & control; 
Blindness/therapy; Corneal opacity
RESUMO | O problema da deficiência visual e da cegueira 
corneal abrange o mundo todo e corresponde à quarta causa 
de cegueira e deficiência visual, com acometimento estimado 
de mais de 16 milhões de pessoas. A associação com várias 
doenças endêmicas, como cegueira infantil, trauma, ceratites 
infecciosas (incluindo herpes, hanseníase e fungos), hipovita-
minose A, diabetes mellitus e outras causas de síndromes de 
olho seco, indicam que a verdadeira frequência é subestimada 
e que os diferentes mecanismos são pouco conhecidos. A baixa 
eficácia na prevenção e tratamento da cicatriz e deformidade 
da córnea permite antecipar que a prevalência da cegueira 
corneal irá crescer no futuro. As razões para o aumento da 
cegueira corneal envolvem fatores ambientais, limitações so-
cioeconômicas para ampliar a assistência à saúde e a modesta 
eficiência das estratégias terapêuticas para resolver o problema 
em grande escala. O presente trabalho traz uma revisão crítica 
dos conceitos associados à cegueira corneal. Essa análise é uma 
etapa necessária para preparar o caminho com o objetivo de 
deixar a caverna que encarcera a cegueira corneal, em analogia 
ao mito de Platão, e melhorar as estratégias para prevenir e 
tratar a cegueira corneal em escala mundial. 
Descritores: Cegueira/epidemiologia; Cegueira/prevenção & 
con trole; Cegueira/terapia; Opacidade da córnea
INTRODUCTION
After a rapid overview of the medical literature and 
lectures presented in clinical conferences about corneal 
diseases, opacity, and corneal blindness, one may arrive 
at four conclusions: a) corneal blindness is a rare and 
distant problem; b) the causes are predictable, and the 
events leading up to corneal blindness are preventable; 
c) most of the causes of corneal injury are treatable, 
and the blindness outcome is avoidable; d) therapeu-
tic approaches are very effective and long lasting(1-3). 
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These optimistic conclusions persist because most of the 
publications addressing corneal diseases fail to mention 
combined frequencies of the causes of corneal blindness, 
the rate of success and long-term outcomes of the available 
treatments, and the limitations to such treatments in the 
less technologically advanced and most populated regions 
of the planet. In the following sections, we will argue 
that corneal blindness is not well defined, that the above 
conclusions are wrong, and that a reduction of the bur den 
of corneal blindness will not be achieved in large seg-
ments of the population using the present strategies.
The analogy with Plato’s cave in this work is justified 
by the apparent scenario where knowledge about corneal 
blindness is “fixed,” which brings to mind the fictional 
condition described by Plato in approximately 380 B.C. 
in “The Republic.” In a dialogue between Socrates and 
his brother Glauco, Socrates described individuals cap-
tive in a cave from a very young age, whose only sources 
of information are noises and shadows projected onto 
the cave wall in front of them. Prevented from leaving 
or even looking back, they are unable to understand 
their situation, until one of them escapes and makes 
contact with the outside world for the first time. After 
returning to the cave, the fugitive reports his experience 
to his former cave-mates and offers to help them escape. 
However, the captive individuals are skeptical and refuse 
the opportunity to be free(4).
The journey to understand the causes, frequency, 
me chanisms, and treatments of corneal opacity and 
blindness is reminiscent of the allegory of Plato’s cave 
in several ways. In the corneal blindness cave, the four 
assumptions enunciated above (a-d) are fed and sup-
ported by information produced by “normal” science, 
as defined by Thomas S. Kuhn in his work addressing 
the structure of scientific revolutions(5). In the cave, 
corneal opacity is a minor issue, well addressed in 
terms of public health and therapeutic strategies, and 
most symptoms can be solved with the refinement of 
certain therapeutic and surgical strategies. However, as 
in Plato’s cave, new knowledge is opening opportuni-
ties to address the challenge of corneal blindness, and 
this new information, which redefines the limits of our 
understanding, is met with skepticism.
Our aims with this review are to show data on the 
prevalence and mechanisms of corneal blindness, to ex-
plain why the problem is not improving, and to highlight 
the frustrating limitations associated with current treat-
ment modalities. In the final section, we will show the 
perspectives for future corneal blindness treatments. In 
continuing with the analogy of Plato’s cave, the concepts 
brought forth by researchers, who left the “normal” 
science on corneal blindness, have been received with 
doses of skepticism.
The burden of corneal blindness
The World Health Organization (WHO) recently 
re defined visual impairment as a visual acuity >0.5 
(or 20/40) and blindness as >0.05 (or 20/400) in the 
better-seeing eye, using the concept of “presented” ins-
tead of “best-corrected” visual acuity. This classification 
does not distinguish treatable from untreatable blind-
ness or functional low vision(6,7).
We can illustrate the difference between a blind eye 
and a blind person by referring to two portraits painted 
by Pablo Picasso in 1903. “Celestina” has an opaque 
(left) cornea but a normal right eye. In “The Blind Man’s 
Meal,” the character is using his hands to identify the 
food, and the face lacks the globe of the eye. These pain-
tings illustrate the distinction between a blind person 
(“The Blind Man’s Meal”) according to the WHO defi-
nition and a person with a blind eye (Figure 1).
From recent estimates, the number of blind indi-
viduals in the world is approximately 36 million, and 
the number of those with moderate to severe visual 
deficiencies is 217 million(8). Taken together, this is a 
population comparable in size to those of the largest 
countries such as Brazil (211 million people) and the 
USA (327 million people)(8-10) (Figure 2).
Figure 1. Pablo Picasso’s portraits from his blue phase, showing (A) a 
woman with an opaque left cornea and a normal right eye and, there-
fore, not matching the criteria for blindness (”Celestina”) and (B) a man 
without eye globes, using his hands to identify the food in front of him 
and who is thus blind not just by Picasso’s but also by the World Health 
Organization’s definition (“The Blind Man’s Meal”). (C) Visual acuity chart 
used to determine visual impairment and blindness with vision in the 
better eye and in the worse eye lower than <0.5 and <0.05, respectively.
A B C
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The most frequent causes of visual impairment and 
blindness are uncorrected refractive errors and cata-
racts. Retinal diseases (including diabetic retinopathy), 
corneal blindness (summing trauma, infection, childhood 
blindness, vitamin A deficiency, and trachoma), and 
glaucoma present similar numbers of affected indivi-
duals(9,11). Glaucoma and retinal diseases have been 
addressed with technological improvements allowing 
early diagnosis and options for treatment that has re-
duced their prevalence among the causes of blindness 
during the past few decades(12-16). Data collection about 
blindness prevalence in population studies is oriented 
towards easily treatable causes in situations where two 
or more conditions contribute similarly to the blindness 
or visual impairment diagnosis(17).
Cataracts and refractive errors persist as large cau-
ses of visual impairment and blindness in studies and 
projections due to barriers against accessing eye health 
facilities and making technologies available in areas distant 
from big cities(18-21). Models of rapid interventions that 
leave communities without an established service have 
clearly failed to prevent or reduce visual impairment 
because of cataracts and refractive errors(22).
Grouped causes of corneal blindness and visual im-
pairment may amount to a total of 16 million affected 
people, but the real numbers are difficult to obtain 
because of differences in search methods, regions eva-
luated, grouping, and analyses, as well as the uncer-
tainty intervals of the estimated rates(9,11). A study in the 
Amazon region of Brazil revealed that pterygium, com-
bined with corneal opacity, accounted for 12% of cases 
of blindness. Another study in Latin America showed 
corneal opacities as responsible for 4% of the cases of 
blindness, in contrast to the results of another study in 
São Paulo, Brazil, where corneal opacity and pterygium 
were not identified as causes of blindness(7,23-27).
Infectious keratitis (caused by bacteria, fungi, viruses, 
or parasites) can cause corneal opacities and blindness. 
However, the frequency of bilateral cases that would fit 
the definition of visual impairment and blindness has 
not been comprehensively registered, and the global 
prevalence remains unknown. Studies have suggested 
that infectious keratitis is the third- or fourth-leading 
cause of corneal blindness, behind pterygium, trauma, 
and surgery(28). Other frequent causes of corneal blind-
ness identified in referral clinics and tertiary hospitals 
such as keratoconus and dysgenetic and dystrophic di-
seases (Peters’ anomaly, sclerocornea, and endothelial 
dystrophies) are underrepresented in population stu-
dies because they may be included in different groups 
as corneal opacities, refractive errors (keratoconus in 
the astigmatic group), and childhood blindness, and a 
systematic criteria to allow merging data from different 
epidemiological studies is lacking. Beyond this issue, an 
under-registered number of individuals with monocular 
visual impairment or binocular asymmetric corneal di-
sease also exist. These observations indicate that more 
individuals will progress to corneal blindness in the 
future, and the numbers will also grow due to better 
registration techniques(8,26). The incidence of tracho-
ma has shown a considerable decline in recent years, 
credited to the SAFE (surgery for trichiasis, antibiotics 
against Chlamydia, facial cleaning, and environmental 
improvements) strategy(14,29). In addition, other risk 
factors for corneal blindness and visual impairment 
tend to grow in the future because of factors, including 
increased life spans, limited access to treatments, and 
underestimated causes related to dry eye disease (DED): 
pterygium, pollutants, excessive ultraviolet light exposu-
re, and the presence of high amounts of toxic agents in 
the environment(7,9,14,18,26-31).
DED is a frequent and increasingly prevalent condi-
tion in the population(32) that is an underestimated risk 
factor for corneal blindness and is frequently associated 
with worse outcomes in diseases resulting in corneal 
blindness(33,34). Corneal opacities and consequent blind-
ness may occur in diseases that cause DED (Figure 3). 
Vitamin A deficiency and trachoma are among the con-
ditions that, when combined, lead to DED and corneal 
blindness(26,35). The prevalence of DED ranges between 
5% and 50%, depending on diagnostic and inclusion 
criteria and geographic regions(32). The comorbidity 
Figure 2. Comparison of the population of USA and Brazil with the 
estimated number of individuals with blindness (top of the middle bar) 
and visual impairment (bottom of the middle bar) throughout the world.
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and pathologic correlations between DED and corneal 
blindness deserve clarification. Moreover, DED causes, 
as potential risk factors for corneal blindness, need 
further studies.
Knowing the causes and managing  
the consequences
Could the rates of corneal blindness due to opacity 
be reduced if we knew its risk factors and demogra-
phics? Intuition and epidemiology say yes; that is what 
is observed in the epidemiologic triangle elaborated in 
the XIX century and its modern variations, which sum-
marize the quote: “to know, to prevent”(36,37). Studies 
on the demographics of an individual with eye trauma 
over three decades have found practical difficulties: 
Patients that attend the clinic for eye trauma seem to be 
all young men with similar risk factors. In other words, 
observations from the 1980s to the 2000s have revealed 
that young, male handworkers are more likely to suffer 
eye traumas (frequently wounding the cornea), mostly in 
the workplace, leading to similar functional, social, and 
economic consequences in all of them(38). In that report, 
approximately 80% of patients were not using protective 
devices, and 30% had had at least another ocular trau-
ma. These data are similar in other regions throughout 
the world(16,28,39,40). The same observations can be extra-
polated to infectious keratitis, especially that caused by 
filamentary fungi, a devastating corneal infection that 
occurs mostly in young, male agricultural workers, and 
which presents few therapeutic options and carries poor 
prognoses for the cornea and vision(41-45). Ibrahim et al. 
found that fungal keratitis has a seasonal prevalence 
associated with low humidity and low temperatures; 
approximately 38% of the cases resulted in therapeutic 
corneal transplants (15% with eye globe evisceration), 
and approximately 60% have a blind eye by the first 
year of follow-up(42,44). Less common but also strongly 
associated with a specific risk factor is Acanthamoeba 
keratitis, where the association is with bad compliance 
with proper contact lens care(46-48).
These observations indicate that preventive mea-
sures can be used to reduce the occurrence of ocular 
trauma and infectious keratitis, two major causes of 
corneal blindness(26,28) (Table 1). However, the frequency 
of these illnesses and the same patient profiles can be 
found throughout the world. Therefore, the myth of 
Plato’s cave applies to corneal blindness, revealing the 
shadows on the wall to be topics on the size of the pro-
blem and its “accidental” causes. Two of the previous 
assumptions can be refuted by data: corneal blindness 
is not rare, and despite knowledge on its epidemiology, 
the incidence remains high.
Established and useful concepts on corneal  
structure and physiology
The cornea is a transparent organ that fills 1 cm2 of 
the area in front of the eyeball. It has a hemispherical 
format and less than 1 mm in thickness. It is almost 90% 
transparent and mostly composed of water and acts as a 
shield for the eye globe. Given its fragile profile, a major 
challenge is to understand how the cornea resists and 
responds to environmental and external aggressions(56).
The surface is protected by a tear film with a complex 
and variable composition(57). Its ingredients are produ-
ced in the exocrine glands present in the ocular surface 
and the goblet and epithelial cells in the epithelial layer. 
The tear film flows as a result of the eyelids blinking at 
an average pace of 10 to 20 times per minute, which 
renews the tear film volume of 10 μL at a rate of 1 μL/
minute(57). This mechanism allows for nutrition, protec-
tion, and stimuli to the cells of the eye that are replaced 
throughout the life of an individual(57,58).
The five layers of the cornea have well-described 
roles that allow it to act as a barrier for the whole eye 
and as an efficient optical lens. The corneal epithelium 
prevents microorganism and toxic agent invasions, the 
endothelium controls the water content, and the stroma 
gives transparency and dioptric power to match the needs 
of the eye. The stroma is found between two membra-
nes: Bowman’s membrane, on the external side of the 
Figure 3. Panel with potential causes of corneal diseases that cause 
blindness, grouped according to similar mechanisms of action.
Barbosa AP, et al.
441Arq Bras Oftalmol. 2020;83(5):437-46
cornea, separates the stroma from the epithelial-layer 
basement membrane, and Descemet’s membrane, on 
the internal side of the cornea, separates the stroma 
from the endothelium(59). Improvements and growth in 
the number of lamellar corneal transplants have drawn the 
attention of cornea surgeons allowing for the characte-
rization of a pre-Descemet membrane, also called Dua’s 
membrane(60), a more compact corneal layer, with few 
keratocytes found between Descemet’s membrane and 
the posterior part of the stroma. After some skepticism, 
this sixth layer is being gradually accepted, and it has 
been found to be associated with the mechanism of 
corneal hydrops and the elastic resistance of the desce-
metocele, at the same time being used as a safety varia-
ble during surgical techniques for deep anterior lamellar 
keratoplasty (a form of corneal transplant)(61,62).
The transparency of the cornea is supported mainly 
by its avascularity. Blood and lymphatic vessels grow 
in the cornea from the corneal limbus in response to 
aggressions and inflammation(63). The avascularity is 
sustained by the permanent expression of soluble vas-
cular endothelial growth factor receptor (sVEGFR) in the 
ocular surface and in the stroma(64). When sVEGFR is 
suppressed, new vessels grow in the cornea(64).
A dense network of nerve fibers detects external, 
harmful stimuli and modulates the reactions of the 
cor nea(65-67). These nerve fibers are linked to the envi-
ronment by a family of transient receptor potential (TRP) 
channels activated by environmental variations in tem-
perature, pH, osmolarity, and mechanical stimuli(68). The 
responses escalate based on the intensity of the stimulus 
and trigger signals capable of attracting inflammatory 
mediators that activate wound healing processes(69,70). 
Interestingly, aggressions limited to the epithelium 
are relatively benign, and the body is able to restore 
the epithelial homeostasis a short time after the initial 
offense; however, aggressions that hit the stroma leave 
long lasting or even permanent scars in the stromal 
layer(71). Two recently described mechanisms help to 
explain this response: The first one involves activation 
of the transient receptor potential vanilloid 1 (TRPV1) 
in epithelial cell cultures by osmolarity, temperature, 
and chemical challenges, which induce secretion of 
inflammatory cytokines (IL-6 and IL-8) through the Mi-
togen-Activated Protein Kinase signaling pathway, but 
also induces corneal epithelial cell migration through 
epidermal growth factor receptor transactivation(72-75). In 
addition, the activation of TRPV channels in keratocytes 
present in a deeper corneal layer (the stroma) promotes 
the secretion of transforming growth factor-beta and 
induces the production of collagen, which is responsible 
for stromal scar formation(70,76-79). Taken together, these 
findings indicate that superficial damage to the epithe-
lium prompts fast wound healing and the preservation 
of transparency despite a painful and inflammatory 
process and deeper injuries to the corneal stroma, which 
destroys the nerve network and jeopardizes the eye 
globe integrity or triggers a mechanism of new vessel 
growth, and strengthens the globe wall (corneal stro-
ma). The delicate structure that provides transparency 
Table 1. Individual or collective strategies to prevent corneal blindness
Type of prevention Description Effects Author, year
Individual Seatbelt use and air bags in automobile 
transportation
Reducing the severity and the grade of visual loss by ocular 
trauma in car accidents
Rao SK et al, 2008(49)
Standard specifications for eye protective 
devices at work and during sportive activities
Significant reduction in eye injuries, face, and head 
attachments due to impact or penetration of a paintball
Tseng VL, et al, 2014(50)
Ocular prophylaxis with 1% silver nitrate, 
0.5% erythromycin ointment, or 1% 
tetracycline hydrochloride to all newborns
Reduction of gonorrheal ophthalmia neonatorum incidence Paediatr Child Health, 2002(51)
Collective Legislation for the control of fireworks use Reduction in the frequency of eye injuries in states in the USA 
with a “Model Law” banning all fireworks, except those used 
in public displays
Kuhn F, 2010(52)
Vitamin A distribution, breastfeeding 
promotion, food fortification, and counseling 
regarding dietary changes
Reduction of keratomalacia incidence Oliva MS et al, 2012(53)
Ivermectin widespread distribution Reduction in the incidence of onchocerciasis in endemic areas Kim YE et al, 2015(54)
SAFE plan Reduction in the frequency of trachoma and parallel rates of 
corneal blindness due to trachoma
Travers A et al, 2013(55)
SAFE= Surgery, Antibiotic, Face washing, and Education
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is abdicated in favor of a scar, which is an opaque and 
stronger barrier against external injuries. To attend that 
natural rule of corneal transparency, mechanisms are in 
place to actively and wisely protect the cornea against 
neovascularization, where dense innervation not only 
provides high sensitivity but also inhibits neovascu-
larization; however, the opposite occurs in response to 
corneal damage, denervation, or nerve network damage 
that allows for neovascularization, which, in turn, inhi-
bits reinnervation(80).
Connections among the corneal layers also respond 
to persistent injuries. One example is the chronic use of 
contact lenses, which leads to changes in the shape of 
endothelial cells; the other example is bullous keratopa-
thy(81,82), which induces stromal edema due to a lack of 
deturgescence control resulting from the loss of endo-
thelial cells and from inflammatory events in the ocular 
surface that induce neovascularization and loss of limbal 
stem and goblet cells(81). In this disease, the repercus-
sions to the stroma and ocular surface may be explained 
by endothelial cell responses to a hypotonic environ-
ment that induce a paracrine secretion of inflammatory 
cytokines, mediated also by the TRPV1 channels(78,83,84).
Taken together, this information helps to clarify 
the initial mediators and steps in the mechanisms 
underlying the fast superficial lesion repairs without 
inflammation. On the other hand, the lesions that hit 
the stroma or the endothelium, either from the external 
or internal side of the eye and whose effects last for a 
long period of time, can induce extensive inflammatory 
processes and a permanent corneal scar.
Epithelial replacement is crucial for faster wound 
healing, and corneal epithelial stem cells asymmetrically 
distributed in niches on the limbal region, called the 
palisades of Vogt, prevent the development of lesions to 
the stromal layer(85-87). During the last three decades, ex-
planations have been provided for how these stem cells 
renew and replace corneal basal epithelial cells(58,88). 
What is not clear is the manner in which epithelial 
wound healing occurs independently of the corneal lim-
bal epithelial cells in certain animal eye lesion models 
and clinical conditions(89-93).
In summary, the five recent observations about the 
corneal structure and the response to injuries are exam-
ples of relevant information brought to the Plato’s cave 
of corneal blindness that, once overcoming the initial 
wave of skepticism and being applied to treatments for 
corneal blindness, will change the epidemiological sce-
nario described above (Table 2). Interestingly, a review 
article authored by Tseng and Tsubota in 1997 advanced 
some of these concepts, although without the steps or 
molecular details(58).
History and present limitations of using  
penetrating keratoplasty for the treatment  
of corneal opacity
The major strategy for fixing an opaque, perforated, 
or melted cornea is a replacement of the organ. Con-
ceptualizations and improvements in the technique have 
been described in other reviews with minimum varia-
tions in terms of historical details(94-96). The first physi-
cian credited with mentioning the possibility of corneal 
replacement was Galen, in Greece, sometime between 
Table 3. Limitations for keratoplasty to revert corneal opacity as a health plan strategy – antiga Box 2
Limitations Analysis Authors
1 Limited availability of corneal 
donation for transplants
Estimated 180,000 keratoplasties/year for an estimated 
total of 16 million people with corneal blindness
Pascolini & Mariotti 2012, Gian et al., 2016(9,100)
2 Limited survival of corneal transplants 
compared to the patients’ life expectancies
The corneal transplant survival is around 12 years, and 
the average life expectancy for patients is longer 
Tan et al, 2008, and Kontis et al, 2017(102,105)
Table 2. Corneal structure updates and transparency mechanisms outside of Plato’s cave – antigo Box 1
Topic Observation Authors
1 Avascularity Active mechanism of corneal vascularity inhibition Ambati et al, 2006, 
Ferrari e t al, 2013(66,82)
2 Sensitivity Ion channels with distinct sensorial and repair responses in different corneal layers Zhang et al, 2007 and Okada et al 2013(71,75)
3 Structure A dua membrane protects the deep cornea Dua et al, 2013(61)
4 Inflammation Interchangeable effect of damage to the inner face of the cornea on the ocular surface Uchino et al, 2006(82)
5 Epithelial stem cells Mechanisms of corneal epithelial replacement based on the limbal niche of stem cells Tseng & Tsubota, 1997, Dua et al, 2005(59, 87)
Barbosa AP, et al.
443Arq Bras Oftalmol. 2020;83(5):437-46
130 and 200 A.D. In the XVIII century, different authors 
conceptualized the possibility of curing corneal blind-
ness. Among them were Erasmus Darwin and Guillau-
me Pellier de Quengsy(94-96). During the XIX century, a 
heterologous strategy (i.e., using the cornea from other 
animal species) was evaluated by several authors, and 
in the XX century, the first homologous transplant took 
place. The remarkable advances in the understanding 
of the biology of grafts, from the 1960 Nobel Prize awar-
ded to Peter Medawar to the studies on mechanisms of 
immunotolerance, clarified the players involved in the 
success and failure of corneal transplantations(63,97). The 
penetrating keratoplasty technique improved conside-
rably after the 1960s with the introduction of four key 
elements: eye banking, surgical microscopy, 10-0 nylon 
sutures, and post-operatory corticotherapy(94,98).
The limitations that impede the success of this proce-
dure can be summarized by two points (Table 3):
1) The limited availability of corneas for all cases 
of corneal blindness. An average of 180,000 corneal 
transplants is performed every year worldwide, far less 
compared with the 16 million patients with corneal 
opacities and low vision or blindness(9,11,99,100). In fact, 
the estimated number of donor corneas or penetrating 
keratoplasties available every year covers only 1 out of 
every 70 cases awaiting this treatment(99). A considera-
ble effort to increase the number of donor tissues and 
the number of facilities to treat those people would be 
necessary to revert corneal blindness with this strategy. 
Considering these numbers, the capacity must grow se-
veral times over to be able to meet the present demand.
2) The survivor curve of corneal transplants worsens 
the limitation of donor corneas. Studies have revealed 
that under favorable conditions, the half-life of a graft is 
approximately 12 years; however, in adverse situations 
such as massive inflammation (therapeutic) or perfo-
rated cornea (tectonic), the mean survival time of the 
grafts is as low as 5 and 2 years, respectively(101-103).
Insisting on the strategy of corneal transplants un-
der these unfavorable conditions is an unwise option 
to revert corneal blindness(100,104-108). Since the 1970s, 
clinical scientists and researchers have worked together 
to develop alternatives or complementary strategies 
to corneal transplants(95,106). The most recent options, 
including pharmaceutical and surgical alternatives to 
avoid corneal blindness, will be addressed in a subse-
quent review, but lying beyond the shadows and the 
skepticism are useful and innovative strategies for trea-
ting corneal blindness, as supported by the concepts 
presented above.
This review summarized the problem of corneal blind-
ness, addressing epidemiological flaws and the mecha-
nisms of the major causes of this disease with the 
limitations of relying on corneal transplants to provide 
a cure and reduce the number of blindness conditions 
worldwide. We believe our review sheds a light on the 
shadows inside the cave and summarizes the work of 
researchers who, upon leaving the cave and observing 
beyond its opening, have returned with rich pieces of in-
formation for understanding the size of the problem, its 
detailed physiopathology, and the fragility of the present 
therapeutic strategies for treating corneal blindness.
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